273. Big problems for Big pharma
Summary
Oliver Ositalo and Lars Frick discuss the Fed's interest rate hike, noting it signals professional independence from political pressure despite inflation concerns. They analyze the pharmaceutical sector, warning that US trade deals and massive patent expirations threaten Big Pharma, while suggesting smaller, niche companies may offer better value. The hosts also review recent presentations from Epiroc, Ambea, and FM Mattsson, highlighting their strong operational trends and growth potential. Finally, they present a bullish case for BHG, arguing its recent restructuring and improving margins…
Topics discussed
Introduction and episode overview
Fed rate hike and market interpretation
Impact of macro factors on equity portfolios
AI safety concerns and tech sector risks
Pharma industry: MFN deals, patents, and AI
Epiroc: Gold prices and competition
Ambea: Care home expansion and margins
FM Mattsson: Strong performance and acquisition
BHG (Bygg Hemma Group): Turnaround case
Closing remarks
Listen ad-free on Castria